HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01150448

A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Cerritos and 27 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study clarity

Study information

Study start dateSeptember 2007
Recruitment status
Completed
Enrollment listed in the registry
212
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States, Belgium, Croatia, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT01150448
Official title
Show the full official title

An Open-Label, Long-Term, Multiple-Dose, Safety and Tolerability, Pharmacokinetic Study of 150 mg eq. Paliperidone Palmitate in the Treatment of Subjects With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Cerritos, United States · National City, United States · San Diego, United States

25 more locations
  • Atlanta, United States
  • Philadelphia, United States
  • Aalst, Belgium
  • Zagreb, Croatia
  • Kuala Lumpur, Malaysia
  • Leszno, Poland
  • Lubliniec, Poland
  • Poznan, Poland
  • Torun, Poland
  • Bratislava, Slovakia
  • Michalovce, Slovakia
  • Rimavská Sobota, Slovakia
  • Gwangju, South Korea
  • Incheon, South Korea
  • Seoul, South Korea
  • Badalona, Spain
  • Barcelona, Spain
  • Madrid, Spain
  • Hualien City, Taiwan
  • Kaohsiung City, Taiwan
  • Tainan, Taiwan
  • Taipei, Taiwan
  • Taoyuan, Taiwan
  • Bangkok, Thailand
  • Chiang Mai, Thailand
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone palmitate Treatment A and Paliperidone palmitate Treatment B.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me